Drug Profile
Insulin transdermal - TransDermics
Latest Information Update: 21 Jan 2022
Price :
$50
*
At a glance
- Originator TransDermics
- Developer Nonindustrial source
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Type 1 diabetes mellitus
Most Recent Events
- 16 Sep 2003 Phase-II clinical trials in Type-1 diabetes mellitus in Croatia (Transdermal)